Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.77 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.77 |
| ▸ | RAB9A | P51151 | 9/20 | 0.65 |
| ▸ | NPC1 | O15118 | 8/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.53 |
| ▸ | BCKDK | O14874 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | PRNP | P04156 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415459 | 0.87 | MCL1 (0.77) | MCL1BCL2L1RAB9ANPC1MAPT | |
| SCHEMBL417349 | 0.87 | MCL1 (1.00) | MCL1BCL2L1RAB9ANPC1MAPT | |
| SCHEMBL9178739 | 0.85 | MCL1 (0.74) | MCL1BCL2L1RAB9ANPC1MAPT | |
| Hydrochloric Acid SCHEMBL11398368 | 0.85 | MCL1 (0.97) | MCL1BCL2L1RAB9ANPC1MAPT | |
| SCHEMBL1254412 | 0.84 | MCL1 (0.51) | MCL1BCL2L1RAB9ANPC1MAPT | |
| SCHEMBL2723054 | 0.83 | BCKDK (0.75) | MCL1BCL2L1RAB9ANPC1MAPT | |
| SCHEMBL13659630 | 0.83 | MCL1 (0.70) | MCL1BCL2L1RAB9ANPC1MAPT | |
| SCHEMBL3058377 | 0.83 | MCL1 (0.54) | MCL1BCL2L1RAB9ANPC1MAPT | |
| SCHEMBL5023563 | 0.83 | MCL1 (0.70) | MCL1BCL2L1RAB9ANPC1MAPT | |
| SCHEMBL14615371 | 0.81 | MCL1 (0.68) | MCL1BCL2L1RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0731800-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO [b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1996-09-18 | — | — | EP | claimed |
| US-5426191-A | Treating substituted cinnamic acids with 4-N,N*-disubstituted aminopyridines, then with thionyl chloride | WARNER-LAMBERT COMPANY (US) | 1995-06-20 | — | — | US | claimed |
| WO-1995015323-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO[b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1995-06-08 | — | — | WO | claimed |
| US-20260070921-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | UNIV KYOTO (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4582430-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | Kyoto University (JP) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024048697-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | 国立大学法人京都大学 | 2024-03-07 | — | — | WO | disclosed |
| US-9409880-B2 | Modulators of TLR3/dsRNA complex and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-08-09 | — | — | US | disclosed |
| US-9375430-B2 | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-28 | — | — | US | disclosed |
| US-8637498-B2 | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-28 | — | — | US | disclosed |
| US-20130085130-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (US) | 2013-04-04 | — | — | US | disclosed |
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-29 | — | — | US | disclosed |
| US-5760062-A | ANTICANCER AGENTS | GERON CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| US-5703116-A | TREATING CANCER | GERON CORPORATION (US) | 1997-12-30 | — | — | US | disclosed |
| US-5608074-A | Process for the synthesis of 5-amino tetrazole derivatives | WARNER-LAMBERT COMPANY (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0731800-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO [b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5440046-A | Angiotensin antagonist, hypotensive agent | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | disclosed |
| US-5426191-A | Treating substituted cinnamic acids with 4-N,N*-disubstituted aminopyridines, then with thionyl chloride | WARNER-LAMBERT COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995015323-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO[b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1995-06-08 | — | — | WO | disclosed |
| US-5350751-A | Hypotensive agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-09-27 | — | — | US | disclosed |
| US-4259336-A | ANALGESIC, ANTIPYRETIC, ANTITHROMBOTIC, ANTIPHLOGISTIC | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070921-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | XBP1, HSPA5, DNAJC10 | MCL1 3585/4885BCL2L1 303/4885RAB9A 1084/4885 |
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, PNLIP, LIPA | MCL1 3086/4885BCL2L1 2842/4885RAB9A 1108/4885 |
| US-20130085130-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS | PNLIP, LIPC, LPL | MCL1 3827/4885BCL2L1 2468/4885RAB9A 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.